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Background:  Hepatitis  C  diagnostics  involve  antibody  screening  and  conﬁrmation  of  current  infection  by
detection  of  HCV  RNA positivity.  In  screening  instruments  with  ﬁxed  pipetting  needle,  there  is a  risk  of
sample  carry-over  contamination.
Objectives:  The  aim  of  this  study  was to evaluate  the  risk  of  such  contamination  in a proposed  clinical
setting.
Study  design:  In  the  present  study,  known  HCV  RNA  positive  (n = 149)  and  negative  (n = 149)  samples
were  analysed  by  anti-HCV  Abbott  in  an  Architect  instrument  in  an  alternating  fashion  in order  to test
for  contamination.
Results:  In  subsequent  retesting  of  the previously  HCV  RNA-negative  samples,  six  samples  (4%)  were
positive  by the  Cobas  Taqman  assay  with a  maximum  level  of  33  IU/mL.  The  results  show  that  there  is
a  risk  for  transfer  of  HCV  in  the  Architect  instrument  but  they  also  show  that the  levels  of HCV  RNA
observed  are  low.
Conclusions:  We  conclude  that  complementary  HCV  RNA  testing  on  samples  identiﬁed  as  anti-HCV  pos-
itive by  screening  can  be recommended  because  the complementary  results  are  reliable  in the majority
of  cases  when  either  HCV  RNA  is negative  or HCV  RNA is positive  with a level  >1000  IU/mL.  In a  minority
of  cases,  with  low  HCV  RNA  after  anti-HCV  antibody  screening,  cross-contamination  should  be  suspected
and  a new  sample  requested  for HCV  RNA  testing.  This  strategy  would  reduce  the need  for  obtaining  a
new  sample  from  the  vast  majority  of patients  with  a newly  discovered  HCV  antibody  positivity.
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. Background
Hepatitis C is a blood-borne viral infection that is mainly trans-
itted by injection drug use, blood products or other nosocomial
outes. Clinical symptoms are often lacking, but there is a long-term
isk of developing cirrhosis or hepatocellular cancer if the infection
Abbreviation: HCV, hepatitis C.
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is left untreated. The diagnosis involves screening for anti-HCV
antibodies and the detection of HCV RNA [1–4].
Testing for HCV infection is performed in risk populations such
as injection drug users, populations without risk prior to certain
health procedures, and subjects for whom other tests indicate
liver disorder. If anti-HCV antibodies are detected, further test-
ing is required in order to establish if an active HCV infection is
present, since antibody-status does not change even if patients
have cleared the infection. Such complementary diagnostics com-
prise HCV core antigen testing by serology or the detection of HCV
RNA by molecular methods. In our current setting, HCV RNA test-
ing is recommended on a new, second blood sample and calling
back the patient again for a second sample is not always success-
ful. The rationale for this recommendation is the potential risk for
false positive HCV RNA as a result of contamination from HCV posi-
tive samples in the serology screening instrument. This means that
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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any patients are reported as possibly infected with HCV because
f anti HCV antibodies being positive, but are never conﬁrmed if
ruly infected or not. If more tests could be performed on the ﬁrst
ample it would save patient time and trouble as well as health care
osts.
. Objectives
The aim of this study was to investigate the risk for cross con-
amination in Architect instruments prior to analysing HCV RNA on
he same sample, and to estimate if that risk justiﬁes the request
hat a new sample be obtained for conﬁrmation testing of patients
ho are positive for anti-HCV.
. Study design
Antibody screening was performed on Architect instruments,
odels i2000 or i2000SR (Abbott Diagnostics, US) according to
he manufacturer’s instruction using the anti-HCV assay (Abbott
iagnostics, Germany). Nucleic acid extraction and HCV RNA
uantiﬁcation was performed on Cobas AmpliPrep/Cobas Taq-
an48 Analyzer with Amplilink 3.2.2 software (Roche Diagnostics
mbH, Germany) using Cobas AmpliPrep/Cobas TaqMan HCV Test,
1 (Roche Diagnostics GmbH, Germany) according to manufac-
urer’s instructions. This method reports samples as “No target
etected” (Negative), <15 IU/mL (HCV RNA detected but below
he linear range of quantiﬁcation), or as a level between 15 and
9,000,000 IU/mL (positive reactions within the range of linear
uantiﬁcation).
Samples stored at −20 ◦C were selected on the basis of pre-
iously being tested for HCV RNA, but not for anti-HCV. Out of
98 samples, 149 had been HCV RNA negative, and 149 HCV
NA positive with mean HCV RNA level of 2,489,389, range
07–27,400,000 IU/mL.
Samples positive and negative for HCV RNA were placed in
very other position in the Architect instrument and re-analysed
or anti-HCV antibodies. This analysis was then followed by HCV
NA analysis of the previously HCV RNA negative samples (n = 149).
. Results
After processing in the Architect instrument the rate of HCV RNA
ositivity in previously HCV RNA-negative samples had become
.05% (6/149), with one sample showing 33.9 IU/mL and 5 sam-
les containing levels <15 IUE/mL. These six samples had been
nalysed in the Architect instrument directly after samples that
ontained HCV RNA levels between 885,000 and 6,680,000 IU/mL
ad been analysed. Forty-eight initially HCV RNA-positive samples
ere reanalysed for HCV RNA and were shown to have lost 33% of
he initial HCV RNA levels.
. Conclusions
We  conclude that carry-over contamination of HCV RNA may
ccur in the Architect instruments using ﬁxed sampling needles,
ut we believe that the impact of this in the diagnostic setting
ould be very low. In the present study, cross contamination was
bserved in 4% of the negative samples that were analysed in
rchitect immediately after an HCV RNA positive sample had been
nalysed. In a typical diagnostic virology laboratory less than 5% of
amples analysed in an Architect instrument are HCV RNA positive,
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indicating that approximately 0.2% of the samples would be con-
taminated by HCV RNA. The likelihood that such a contaminated
sample would be analysed for HCV RNA is probably also low, and if
this were the case, the level of detected HCV RNA would be very low.
Still, it is important to be aware of this risk. Samples from patients
who have not received any treatment usually show relatively high
HCV RNA levels. Therefore, if a very low HCV RNA level is detected in
a patient not being treated for hepatitis C, cross contamination has
to be suspected and should be conﬁrmed if the sample had orig-
inally been analysed in a serology instrument prior to HCV RNA
testing. In such cases, testing of a new sample is required to either
verify or rule out present infection. In patients treated for hepatitis
C, detection of false, low HCV RNA levels would be of greater impor-
tance, because the results may  inﬂuence the decision to continue
or stop treatment. Therefore, HCV RNA quantiﬁcation during treat-
ment should not be performed on samples that have been used for
serological testing. On the other hand, antibody testing on samples
from patients being treated for HCV is not necessary and is rarely
warranted since the serological status does not inﬂuence treatment
strategy.
Our results support the position that samples that have been
analysed in serology instruments should be recommended for HCV
RNA testing, because both HCV RNA positive results with high lev-
els (>1000 IU/mL) and HCV RNA negative results are reliable, and
such results are present in the vast majority of samples. Low levels
of HCV RNA (<1000) in samples previously analysed in a screening
instrument with ﬁxed needles should not be accepted and in such
cases, a new sample should be requested. With this caveat, the
approach of analysing HCV RNA on samples that have been analysed
in a serology instrument is rational and reliable.
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